Fate Therapeutics, Inc. (FATE) financial statements (2021 and earlier)

Company profile

Business Address 3535 GENERAL ATOMICS COURT
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1002507118319118336
Cash and cash equivalents1002507118319118336
Receivables   111 
Other undisclosed current assets12756943143044
Total current assets:22730616518620521480
Noncurrent Assets
Operating lease, right-of-use asset2323  
Property, plant and equipment111098543
Long-term investments and receivables39      
Long-term investments39      
Contract with customer, asset, net122222 
Restricted cash and investments0000000
Other noncurrent assets00  1  
Other undisclosed noncurrent assets  2424   
Total noncurrent assets:75353534863
TOTAL ASSETS:30234020022121322083
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21201515151512
Accounts payable6655454
Accrued liabilities1514101011108
Deferred revenue33  
Debt21654232
Contract with customer, liability57832
Other undisclosed current liabilities3243211
Total current liabilities:28412929272316
Noncurrent Liabilities
Long-term debt and lease obligation2526911121213
Long-term debt, excluding current maturities  911121213
Operating lease, liability2526  
Liabilities, other than long-term debt446711112
Accounts payable and accrued liabilities  11100
Deferred revenue44  
Contract with customer, liability5688 
Deferred rent credit    321
Total noncurrent liabilities:29301518242215
Total liabilities:57714547514531
Stockholders' equity
Stockholders' equity attributable to parent24526812814616017452
Preferred stock0000000
Common stock0000000
Additional paid in capital628623456451446443304
Accumulated other comprehensive income (loss)000 (0)(0)(0)
Accumulated deficit(384)(355)(329)(305)(285)(269)(253)
Total stockholders' equity:24526812814616017452
Other undisclosed liabilities and equity112828110
TOTAL LIABILITIES AND EQUITY:30234020022121322083

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:3233211
Operating expenses(32)(30)(27)(23)(18)(18)(21)
Operating loss:(29)(27)(24)(20)(17)(17)(20)
Nonoperating income (expense)11111(0)(0)
Other nonoperating income (expense)11111(0)(0)
Interest and debt expense(1)(0)(0)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(29)(27)(24)(20)(16)(17)(20)
Other undisclosed net income1  00  
Net loss:(28)(27)(24)(20)(16)(17)(20)
Other undisclosed net income attributable to parent 00  00
Net loss available to common stockholders, diluted:(28)(27)(23)(20)(16)(17)(20)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(28)(27)(24)(20)(16)(17)(20)
Other undisclosed comprehensive income (loss)(0)010000
Comprehensive loss, net of tax, attributable to parent:(28)(27)(23)(20)(16)(17)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: